Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access
At the heart of the agreement is Pfizer’s $70 billion commitment to U.S.-based manufacturing and an exemption from tariffs for three years. While the reaction was mostly positive from Wall Street, other observers noted that the benefits for patients are unclear at best.
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access Read More »
